What is MOgene?
Established in 2004, MOgene operates at the intersection of high-throughput genomics and consultative bioinformatics. The company provides a comprehensive suite of services, including biopharma genomic analysis, agritech innovation, and microbiome research. By serving a diverse clientele ranging from government facilities to multinational pharmaceutical corporations, MOgene has carved out a defensible market position as a high-precision service provider. Their methodology integrates advanced sequencing technologies with deep domain expertise, ensuring that complex biological data is translated into actionable insights for drug discovery and agricultural development. This technical proficiency, combined with a long-standing reputation for quality, positions MOgene as a cornerstone entity in the modern biotechnology ecosystem.
How much funding has MOgene raised?
MOgene has raised a total of $373K across 2 funding rounds:
Debt
$150K
Debt
$223K
Debt (2020): $150K with participation from PPP
Debt (2021): $223K led by PPP
Key Investors in MOgene
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for MOgene?
With the recent capital deployment, MOgene is strategically positioned to accelerate its technological roadmap and expand its footprint in the precision medicine market. The focus will likely shift toward enhancing bioinformatics capabilities and scaling high-throughput sequencing capacity to meet the rising demand for personalized therapeutic development. As the company navigates this late-stage growth phase, the emphasis remains on maintaining operational excellence while exploring new frontiers in agritech and microbiome diagnostics. By reinforcing its consultative service model, MOgene is poised to capture additional market share, effectively bridging the gap between raw genomic data and clinical or commercial application in an increasingly data-driven life sciences landscape.
See full MOgene company page
